Abstract • 195
A major challenge in treatment of childhood ALL is cure following relapse despite multiagent chemotherapy. Combining immunotoxin with conventional chemotherapy is an alternative strategy to enhance antileukemia effect with non-overlapping toxicities. B43-PAP immunotoxin is directed against the CD19 antigen. CD 19+ lymphoid cells show a high affinity for the B43 monoclonal antibody and when bound CD19+ lymphoid cells are capable of internalization of the B43-PAP immunotoxin resulting in inhibition of protein synthesis. A Phase I study of B43-PAP immunotoxin was performed in children with relapsed ALL who were concurrently receiving a standard 4-drug reinduction (vincristine, prednisone, L'asparaginase, daunomycin). The goals of the study were to assess toxicity of B43-PAP immunotoxin at two different dose levels and feasibility of administration with standard 4-drug reinduction. Patients with relapsed ALL (>50% CD19+) <21 years of age with normal renal, liver, cardiac and pulmonary functions were eligible. Patients received B43-PAP immunotoxin daily on days 9-13 and 21-25. Twenty-four patients were entered on study (21 received at least one dose of immunotoxin), 18 were evaluable for toxicity, 15 for response. The median age was 10 (range 4-17 years). One patient at 1 mg/m2/d experienced grade 4 myalgias. Dose-limiting toxicity was seen in 3 (out of 11 patients) at 1.5 mg/m2/d. Two patients experienced grade 3 or 4 transaminase elevations. There were ten complete remissions, two patients reached a partial remission and three had progressive disease or no response. We conclude that the combination of B43-PAP immunotoxin can be given safely in patients with ALL with a 4-drug induction. In light of the efficacy of this approach, we have implemented this in one of the treatment arms of our protocol for newly diagnosed high risk ALL.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Seibel, N., Krailo, M., O'Neill, K. et al. Phase I Study of B43-PAP Immunotoxin in Combination with Standard 4-Drug Induction for Patients with CD 19+ Acute Lymphoblastic Leukemia (ALL) in Relapse, A Children's Cancer Group Study. Pediatr Res 45 (Suppl 5), 775 (1999). https://doi.org/10.1203/00006450-199905010-00225
Issue Date:
DOI: https://doi.org/10.1203/00006450-199905010-00225
This article is cited by
-
Application of immunotherapy in pediatric leukemia
Current Hematologic Malignancy Reports (2009)